Cadrenal appointed John P. Sharp as Interim Chief Financial Officer effective June 25, 2026, and director Steven Zelenkofske resigned from the Board effective June 30, 2026.
| IndividualJohn P. SharpSteven ZelenkofskeGlynn Wilson | RoleInterim Chief Financial OfficerClass III DirectorDirector (moved from Class I to Class III) | Type of ChangeAppointedResignedResigned and Reappointed (class realignment) | Effective DateJune 25, 2026June 30, 2026June 29, 2026 (resignation from Class I) / Reappointed effective immediately | ReasonCompany appointment; search for permanent CFO underwayNot the result of any disagreement with the CompanyBoard realignment to create three classes as nearly equal in size as practicable | Replacement InfoQuang X. Pham ceased serving as Interim CFONot disclosedN/A | Background DetailsAge 61; Senior Director at Lohman & Associates; >30 years finance experience; CFO roles at Skye Bioscience (since Mar 31, 2026), SaNOtize (Dec 2022–Oct 2025), PhaseBio (Apr 2016–Nov 11, 2022), Ligand (Apr 2007–Mar 2014); former PwC auditor; BS in Business Administration (Accounting); CPA (inactive CA)N/AReappointed to Audit, Nominating & Corporate Governance, and Compensation Committees; will receive standard non-employee director compensation | Board/Committee Role ChangesNot disclosedNot disclosedAppointed to Audit Committee, Nominating & Corporate Governance Committee, and Compensation Committee |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.